Until recently, hepatitis E virus (HEV) was thought not to occur in developed countries. It is now clear that locally acquired HEV is common in such settings. HEV infection acquired in these areas differs from that in developing countries in a number of important aspects: it is caused by genotype 3 (and 4 in China and Japan), it mainly affects middle-aged/elderly males and it is zoonotic with a porcine primary host. Pig herds worldwide are infected with HEV genotype 3 and HEV has been found in the human food chain in a number of developed countries. However, the route of transmission is not fully understood, since most cases are not obviously associated with pigs/pig products. HEV can be transmitted by blood transfusion and surprisingly high numbers of asymptomatic blood donors are viremic at the time of donation: Germany 1:1,200, Netherlands 1:2,671, England 1:2,848. Our understanding of the clinical phenotype of HEV infection in humans has undergone a sea-change in recent years. Previously, HEV was thought to cause only acute self-limiting hepatitis. However, HEV may cause persistent disease in the immunocompromised. Patients with chronic HEV infection have no symptoms, but some develop rapidly progressive liver cirrhosis. The full clinical spectrum of HEV is still emerging. HEV has important extra-hepatic manifestations, which deserve further investigation. For example, HEV can cause a wide range of neurological illness. In particular, very recent data suggest that Guillain-Barré syndrome and neuralgic amyotrophy are associated with locally acquired HEV in approximately 5 and 10% of the cases, respectively.

Keywords:
Hepatitis E virus, Porcine zoonosis, Neurological injury, Cirrhosis, Decompensated chronic liver disease
1.
Purcell RH, Emerson SU: Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008;48:494-503.
2.
Rein DB, Stevens GA, Theaker J, et al: The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012;55:988-997.
3.
Hadler SC: Global impact of hepatitis A virus infection: changing patterns; in Hollinger FB, Lemon SM, Margolis HS (eds): Viral Hepatitis and Liver Disease. Baltimore, Williams & Wilkins, 1991, pp 14-20.
4.
Dalton HR, Bendall R, Ijaz S, Banks M: Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698-709.
5.
Dalton HR, Stableforth W, Thurairajah P, et al: Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol 2008;20:784-790.
6.
Mansuy JM, Peron JM, Abravanel F, et al: Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol 2004;74:419-424.
7.
Dalton HR, Fellows HJ, Gane EJ, et al: Hepatitis E in New Zealand. J Gastroenterol Hepatol 2007;22:1236-1240.
8.
Public Health England: Hepatitis E: symptoms, transmission, treatment and prevention, 2014. https://www.gov.uk/government/publications/hepatitis-e-symptoms-transmission-prevention-treatment/hepatitis-e-symptoms-transmission-treatment-and-prevention (accessed September 11, 2015).
9.
Hewitt PE, Ijaz S, Brailsford SR, et al: Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014;384:1766-1773.
10.
Kamar N, Bendall R, Legrand-Abravanel F, et al: Hepatitis E. Lancet 2012;379:2477-2488.
11.
Colson P, Romanet P, Moal V, et al: Autochthonous infections with hepatitis E virus genotype 4, France. Emerg Infect Dis 2012;18:1361-1364.
12.
Garbuglia AR, Scognamiglio P, Petrosillo N, et al: Hepatitis E virus genotype 4 outbreak, Italy, 2011. Emerg Infect Dis 2013;19:110-114.
13.
Halbur PG, Kasorndorkbua C, Gilbert C, et al: Comparative pathogenesis of infection of pigs with hepatitis E viruses recovered from a pig and a human. J Clin Microbiol 2001;39:918-923.
14.
Legrand-Abravanel F, Mansuy JM, Dubois M, et al: Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis 2009;15:110-114.
15.
Fernandez-Barredo S, Galiana C, Garcia A, et al: Detection of hepatitis E virus shedding in feces of pigs at different stages of production using reverse transcription-polymerase chain reaction. J Vet Diagn Invest 2006;18:462-465.
16.
Hartl J, Otto B, Webb GW, Madden RG, Kriston L, Vettorazzi E, Lohse AW, Woolson KL, Dalton HR, Pischke S: Hepatitis E seroprevalence in Europe: a meta-analysis. Emerg Infect Dis [submitted].
17.
Berto A, Martelli F, Grierson S, et al: Hepatitis E virus in pork food chain, United Kingdom, 2009-2010. Emerg Infect Dis 2012;18:1358-1360.
18.
Colson P, Borentain P, Queyriaux B, et al: Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 2010;202:825-834.
19.
Tei S, Kitajima N, Takahashi K, et al: Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003;362:371-373.
20.
Barnaud E, Rogee S, Garry P, et al: Thermal inactivation of infectious hepatitis E virus in experimentally contaminated food. Appl Environ Microbiol 2012;78:5153-5159.
21.
Clayson ET, Shrestha MP, Vaughn DW, et al: Rates of hepatitis E virus infection and disease among adolescents and adults in Kathmandu, Nepal. J Infect Dis 1997;176:763-766.
22.
Tran HT, Ushijima H, Quang VX, et al: Prevalence of hepatitis virus types B through E and genotypic distribution of HBV and HCV in Ho Chi Minh City, Vietnam. Hepatol Res 2003;26:275-280.
23.
Bernal W, Smith HM, Williams R: A community prevalence study of antibodies to hepatitis A and E in inner-city London. J Med Virol 1996;49:230-234.
24.
Bendall R, Ellis V, Ijaz S, et al: A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 2010;82:799-805.
25.
Mansuy JM, Bendall R, Legrand-Abravanel F, et al: Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 2011;17:2309-2312.
26.
Dalton HR, Fellows HJ, Stableforth W, et al: The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007;26:1429-1435.
27.
Woolson KL, Forbes A, Vine L, et al: Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther 2014;40:1282-1291.
28.
Huang S, Zhang X, Jiang H, et al: Profile of acute infectious markers in sporadic hepatitis E. PLoS One 2010;5:e13560.
29.
Chauhan A, Jameel S, Dilawari JB, et al: Hepatitis E virus transmission to a volunteer. Lancet 1993;341:149-150.
30.
Clayson ET, Myint KS, Snitbhan R, et al: Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 1995;172:927-933.
31.
Kumar Acharya S, Kumar Sharma P, Singh R, et al: Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007;46:387-394.
32.
Blasco-Perrin H, Madden RG, Stanley A, et al: Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study. Aliment Pharmacol Ther 2015;42:574-581.
33.
Teshale EH, Hu DJ, Holmberg SD, et al: The two faces of hepatitis E virus. Clin Infect Dis 2010;51:328-334.
34.
Peron JM, Abravanel F, Guillaume M, et al: Treatment of autochthonous acute hepatitis E with short term ribavirin: a multicenter retrospective study. Liver Int 2015, Epub ahead of print.
35.
Kamar N, Selves J, Mansuy JM, et al: Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-817.
36.
Gerolami R, Moal V, Colson P: Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008;358:859-860.
37.
Kamar N, Garrouste C, Haagsma EB, et al: Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011;140:1481-1489.
38.
Pischke S, Stiefel P, Franz B, et al: Chronic hepatitis E in heart transplant recipients. Am J Transplant 2012;12:3128-3133.
39.
Pas SD, de Man RA, Mulders C, et al: Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis 2012;18:869-872.
40.
van der Eijk AA, Pas SD, Cornelissen JJ, et al: Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2014;27:309-315.
41.
Dalton HR, Bendall RP, Keane FE, et al: Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009;361:1025-1027.
42.
Perumpail RB, Ahmed A, Higgins JP, et al: Fatal accelerated cirrhosis after imported HEV genotype 4 infection. Emerg Infect Dis 2015;21:1679-1681.
43.
Kamar N, Abravanel F, Lhomme S, et al: Hepatitis E virus: chronic infection, extra-hepatic manifestations, and treatment. Clin Res Hepatol Gastroenterol 2015;39:20-27.
44.
Oomes PG, van der Meche FG, Kleyweg RP: Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Dutch Guillain-Barré study group. Neurology 1996;46:96-100.
45.
van den Berg B, van der Eijk AA, Pas SD, et al: Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology 2014;82:491-497.
46.
van Eijk JJ, Madden RG, van der Eijk AA, et al: Neuralgic amyotrophy and hepatitis E virus infection. Neurology 2014;82:498-503.
47.
van Alfen N, van Engelen BG: The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 2006;129(pt 2):438-450.
48.
Wallace SJ, Webb GW, Madden RG, Dalton HC, Palmer J, Dalton RT, Pollard A, Martin R, Panayi V, Bennett G, Bendall RP, Dalton HR: Hepatitis E: whom should we test? J Chem Pathol [submitted].
49.
Kamar N, Izopet J, Tripon S, et al: Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-1120.
50.
Pawlotsky JM: Hepatitis E screening for blood donations: an urgent need? Lancet 2014;384:1729-1730.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.